[Lieyun Network (WeChat:ilieyun
[Beijing] Reported on September 8
Lieyun.com recently learned that tumor immunotherapy technology developer “Shanghai Hengrun Dasheng Biotechnology Co., Ltd.” announced the completion of a RMB 200 million Series B+ financing round, with participation from investment institutions including SPINNOTEC, Sino-Singapore Connectivity Private Equity Fund Management Co., Ltd., Wanhui Capital, Dongtai Chongye, New Silk Road Investment, Xinyi Capital, Junchenda Capital, and Hengzhen Partnership.
It is understood that,The funds raised in this offering will be used to support the smooth conduct of registration clinical trials for three CAR-T approvals of Hengrun Dasheng, facilitate the industrialization of domestically developed CAR-T products, and advance the research and development of innovative pipeline products targeting solid tumors, including new-target CAR-T, TCR-T, CAR-NK, and oncolytic viruses.
According to the information displayed on the Tianyancha app, Shanghai Hengrun Dasheng Biotechnology Co., Ltd. was established in July 2015, with Li Guoshun serving as its legal representative.Hengrun Dasheng is a developer of tumor immunotherapy technologies, leveraging CAR-T technology to provide precision treatment solutions based on biological and cellular technologies for cancer patients. The company has established central clinical trial platforms in multiple regions, including Beijing, Jiangsu, Chongqing, and Henan.
Shanghai Hengrun Dasheng Biotechnology Co., Ltd. has leveraged the research and development and application of tumor immunotherapy technologies as its strategic entry point, establishing a R&D landscape dominated by CAR-T technology, with parallel advancement of multiple projects including TCR-T targeting solid tumors, CAR-NK, and oncolytic viruses. The company simultaneously translates the latest domestic and international advancements in tumor immunotherapy into clinical practice, actively promoting the clinical application of innovative tumor immunotherapies to provide cutting-edge, precision treatment solutions for cancer patients.
After five years of development, Shanghai Hengrun Dasheng Biotechnology Co., Ltd. has assembled a comprehensive, high-caliber team capable of independently driving the entire process from early-stage R&D to CMC studies, IND submissions, and registrational clinical trials. Leveraging its outstanding R&D capabilities, the company was the first in China to secure three approvals for CAR-T registrational clinical trials, making it the Chinese enterprise with the largest number of such approvals for CAR-T therapies targeting hematologic malignancies.
Currently, the registrational clinical trials for three approved products are being conducted simultaneously at renowned Grade-A tertiary hospitals in China, making the company the enterprise with the highest number of CAR-T registrational clinical trials initiated domestically. Shanghai Hengrun Dasheng Biotechnology Co., Ltd. has successively secured government-funded projects totaling over RMB 80 million and independently undertakes a national-level project. The company has established a nearly 5,000-square-meter R&D and pilot-scale platform in Zhangjiang. Meanwhile, the construction of its large-scale CAR-T GMP manufacturing center, covering an area of 11,000 square meters at the Shanghai Zhangjiang-Jinshan Biopharmaceutical Base, is nearing completion (see figure below). This facility will prepare for large-scale production, facilitating the industrialization of affordable CAR-T products for Chinese patients and benefiting more individuals with cancer.